A New Antipsychotic for Schizophrenia: Xanomeline and Trospium (Cobenfy).
Saved in:
| Title: | A New Antipsychotic for Schizophrenia: Xanomeline and Trospium (Cobenfy). |
|---|---|
| Authors: | Mills, Jeremy |
| Source: | Issues in Mental Health Nursing. Dec2024, Vol. 45 Issue 12, p1364-1367. 4p. |
| Subjects: | Drug therapy for schizophrenia, Combination drug therapy, Blood-brain barrier, Antipsychotic agents, United States. Food & Drug Administration, Drug approval, Pharmacy information services, Dopamine antagonists, Muscarinic antagonists, Drug development, Psychopharmacology, Muscarinic agonists, Therapeutics, Pharmacodynamics |
| Abstract: | The article discusses the groundbreaking approval of a new antipsychotic medication, Cobenfy (xanomeline and trospium), which marks a significant shift in the treatment of schizophrenia by targeting acetylcholine instead of dopamine. This approval represents a major departure from traditional antipsychotics, which have predominantly focused on dopaminergic mechanisms. |
| Database: | Psychology and Behavioral Sciences Collection |
Be the first to leave a comment!
